Adam Kalbermatten Buys Shares of KRMD $KRMD
Key Points
- Adam Kalbermatten bought 7,500 shares of KORU Medical Systems, Inc. ($KRMD) worth $29,475.
- $KRMD last traded around $3.87.
Adam Kalbermatten, President-Chief Commercial Off at KORU Medical Systems, Inc. ($KRMD), bought 7,500 shares at an average price of $3.93, for a total transaction of $29,475. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
KORU Medical Systems, Inc. ($KRMD) Stock
KORU Medical Systems, Inc. Earnings
Analysts Set New Price Targets
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.